Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
The Other Bearish Biotech ETF Is Looking Groovy, Too
What Are Payors Saying About Managed Care Giants?
FDA OKs Cholesterol Drug (Investor's Business Daily)
Related AGN
Allergan Gedeon Richter Plc. to Present Data from Cariprazine Trials at ECNP Annual Meeting in Amsterdam
13F Recap: The Most Popular (And Unpopular) Stocks Of Q2
Expect Perrigo To Grow, With Or Without Hostile Mylan (Investor's Business Daily)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Aug 2015BarclaysMaintainsEqual-weight
Aug 2015Brean CapitalMaintainsBuy
Aug 2015Morgan StanleyMaintainsOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Get Benzinga's Newsletters